Vulvovaginal Candidiasis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Vulvovaginal Candidiasis - Pipeline Review, H1 2016', provides an overview of the Vulvovaginal Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis - The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects - The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vulvovaginal Candidiasis Overview 6 Therapeutics Development 7 Pipeline Products for Vulvovaginal Candidiasis - Overview 7 Vulvovaginal Candidiasis - Therapeutics under Development by Companies 8 Vulvovaginal Candidiasis - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Unknown Stage Products 11 Vulvovaginal Candidiasis - Products under Development by Companies 12 Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development 13 Cidara Therapeutics, Inc. 13 Grupo Ferrer Internacional, S.A. 14 NovaDigm Therapeutics, Inc. 15 Scynexis, Inc. 16 TGV-Laboratories 17 Viamet Pharmaceuticals, Inc. 18 Vulvovaginal Candidiasis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 arasertaconazole - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CD-101 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 MH-010 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Myc-102 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 NDV-3 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 NDV-3A - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 SCY-078 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 VT-1161 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Vulvovaginal Candidiasis - Recent Pipeline Updates 40 Vulvovaginal Candidiasis - Dormant Projects 47 Vulvovaginal Candidiasis - Discontinued Products 48 Vulvovaginal Candidiasis - Product Development Milestones 49 Featured News & Press Releases 49 Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis 49 Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections 49 Jan 11, 2016: Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV 50 Dec 01, 2015: SCYNEXIS Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis 51 Apr 24, 2015: Viamet to Provide Update on VT-1161, Novel Antifungal Program at ECCMID 2015 52 Feb 12, 2015: Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis 52 Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 53 Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis 53 Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161 54 Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Number of Products under Development for Vulvovaginal Candidiasis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Comparative Analysis by Unknown Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Vulvovaginal Candidiasis - Pipeline by Cidara Therapeutics, Inc., H1 2016 13 Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 14 Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H1 2016 15 Vulvovaginal Candidiasis - Pipeline by Scynexis, Inc., H1 2016 16 Vulvovaginal Candidiasis - Pipeline by TGV-Laboratories, H1 2016 17 Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Vulvovaginal Candidiasis Therapeutics - Recent Pipeline Updates, H1 2016 40 Vulvovaginal Candidiasis - Dormant Projects, H1 2016 47 Vulvovaginal Candidiasis - Discontinued Products, H1 2016 48
List of Figures
Number of Products under Development for Vulvovaginal Candidiasis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Targets, H1 2016 20 Number of Products by Stage and Targets, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 22 Number of Products by Stage and Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.